Cytomx Therapeutics Stock Total Asset

CTMX Stock

USD 2.39 0.04 1.70%

By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess CytomX Therapeutics' long-term financial health and intrinsic value.

	Last Reported	Projected for Next Year
Total Assets	120.5 M	114.5 M
Intangibles To Total Assets	0.01	0.01

Total Assets is likely to drop to about 114.5 M in 2025. Intangibles To Total Assets is likely to drop to 0.01 in 2025.

Build AI portfolio with CytomX Stock

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

CytomX Therapeutics Company Total Asset Analysis

CytomX Therapeutics' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Total Asset

Tangible Assets

+

Intangible Assets

More About Total Asset | All Equity Analysis

Current CytomX Therapeutics Total Asset

120.53 M

Most of CytomX Therapeutics' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CytomX Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

CytomX Total Asset Driver Correlations

Understanding the fundamental principles of building solid financial models for CytomX Therapeutics is extremely important. It helps to project a fair market value of CytomX Stock properly, considering its historical fundamentals such as Total Asset. Since CytomX Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CytomX Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CytomX Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Good Will	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Net Tangible Assets	Deferred Long Term Liab	Short Long Term Debt	Capital Surpluse	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.69	0.52	-0.92	-0.41	0.7	0.18	0.19	0.87	0.85	1.0	0.56	-0.31	0.19	0.42	0.84	0.66	0.19	0.42	0.1	-0.06	0.19
Total Stockholder Equity	0.69		-0.04	-0.6	0.01	0.77	-0.33	0.07	0.64	0.28	0.71	0.76	0.08	0.07	0.23	0.91	0.24	0.07	0.02	0.54	0.26	0.07
Current Deferred Revenue	0.52	-0.04		-0.37	-0.93	0.04	0.54	-0.15	0.6	0.74	0.49	0.03	-0.89	-0.15	0.26	0.31	0.81	-0.15	0.88	-0.72	-0.79	-0.15
Net Debt	-0.92	-0.6	-0.37		0.27	-0.69	-0.29	-0.26	-0.66	-0.8	-0.92	-0.46	0.16	-0.26	-0.36	-0.73	-0.52	-0.26	-0.31	-0.2	-0.1	-0.26
Retained Earnings	-0.41	0.01	-0.93	0.27		0.05	-0.45	0.46	-0.52	-0.64	-0.38	0.01	0.97	0.46	-0.33	-0.3	-0.88	0.46	-0.95	0.72	0.93	0.46
Accounts Payable	0.7	0.77	0.04	-0.69	0.05		0.05	0.33	0.58	0.37	0.71	0.82	0.19	0.33	0.26	0.83	0.09	0.33	-0.09	0.31	0.33	0.33
Net Receivables	0.18	-0.33	0.54	-0.29	-0.45	0.05		-0.02	0.2	0.47	0.18	0.05	-0.37	-0.02	-0.05	0.01	0.32	-0.02	0.35	-0.7	-0.39	-0.02
Good Will	0.19	0.07	-0.15	-0.26	0.46	0.33	-0.02		-0.06	-0.03	0.2	0.04	0.43	1.0	-0.07	0.06	-0.44	1.0	-0.32	0.32	0.62	1.0
Short Term Investments	0.87	0.64	0.6	-0.66	-0.52	0.58	0.2	-0.06		0.78	0.88	0.7	-0.4	-0.06	0.28	0.83	0.7	-0.06	0.43	-0.11	-0.26	-0.06
Total Liab	0.85	0.28	0.74	-0.8	-0.64	0.37	0.47	-0.03	0.78		0.84	0.26	-0.52	-0.03	0.43	0.53	0.82	-0.03	0.58	-0.27	-0.37	-0.03
Total Current Assets	1.0	0.71	0.49	-0.92	-0.38	0.71	0.18	0.2	0.88	0.84		0.6	-0.28	0.2	0.38	0.85	0.64	0.2	0.39	0.13	-0.03	0.2
Short Term Debt	0.56	0.76	0.03	-0.46	0.01	0.82	0.05	0.04	0.7	0.26	0.6		0.12	0.04	-0.07	0.8	0.15	0.04	-0.09	0.24	0.2	0.04
Intangible Assets	-0.31	0.08	-0.89	0.16	0.97	0.19	-0.37	0.43	-0.4	-0.52	-0.28	0.12		0.43	-0.27	-0.19	-0.83	0.43	-0.98	0.7	0.93	0.43
Common Stock	0.19	0.07	-0.15	-0.26	0.46	0.33	-0.02	1.0	-0.06	-0.03	0.2	0.04	0.43		-0.07	0.06	-0.44	1.0	-0.32	0.32	0.62	1.0
Property Plant Equipment	0.42	0.23	0.26	-0.36	-0.33	0.26	-0.05	-0.07	0.28	0.43	0.38	-0.07	-0.27	-0.07		0.28	0.45	-0.07	0.32	-0.09	-0.24	-0.07
Net Tangible Assets	0.84	0.91	0.31	-0.73	-0.3	0.83	0.01	0.06	0.83	0.53	0.85	0.8	-0.19	0.06	0.28		0.45	0.06	0.29	0.2	0.0	0.06
Deferred Long Term Liab	0.66	0.24	0.81	-0.52	-0.88	0.09	0.32	-0.44	0.7	0.82	0.64	0.15	-0.83	-0.44	0.45	0.45		-0.44	0.85	-0.42	-0.72	-0.44
Short Long Term Debt	0.19	0.07	-0.15	-0.26	0.46	0.33	-0.02	1.0	-0.06	-0.03	0.2	0.04	0.43	1.0	-0.07	0.06	-0.44		-0.32	0.32	0.62	1.0
Capital Surpluse	0.42	0.02	0.88	-0.31	-0.95	-0.09	0.35	-0.32	0.43	0.58	0.39	-0.09	-0.98	-0.32	0.32	0.29	0.85	-0.32		-0.59	-0.84	-0.32
Net Invested Capital	0.1	0.54	-0.72	-0.2	0.72	0.31	-0.7	0.32	-0.11	-0.27	0.13	0.24	0.7	0.32	-0.09	0.2	-0.42	0.32	-0.59		0.83	0.32
Net Working Capital	-0.06	0.26	-0.79	-0.1	0.93	0.33	-0.39	0.62	-0.26	-0.37	-0.03	0.2	0.93	0.62	-0.24	0.0	-0.72	0.62	-0.84	0.83		0.62
Capital Stock	0.19	0.07	-0.15	-0.26	0.46	0.33	-0.02	1.0	-0.06	-0.03	0.2	0.04	0.43	1.0	-0.07	0.06	-0.44	1.0	-0.32	0.32	0.62

Click cells to compare fundamentals

CytomX Total Asset Historical Pattern

Today, most investors in CytomX Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various CytomX Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of CytomX Therapeutics total asset as a starting point in their analysis.

CytomX Therapeutics Total Asset

Timeline

Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.

Competition

Predict CytomX Therapeutics

Total Assets Over Time

CytomX Total Assets

Total Assets

114.51 Million

At this time, CytomX Therapeutics' Total Assets are fairly stable compared to the past year.

Based on the latest financial disclosure, CytomX Therapeutics has a Total Asset of 120.53 M. This is 98.4% lower than that of the Biotechnology sector and 93.9% lower than that of the Health Care industry. The total asset for all United States stocks is 99.59% higher than that of the company.

CytomX Total Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CytomX Therapeutics' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CytomX Therapeutics could also be used in its relative valuation, which is a method of valuing CytomX Therapeutics by comparing valuation metrics of similar companies.

CytomX Therapeutics is currently under evaluation in total asset category among its peers.

CytomX Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of CytomX Therapeutics from analyzing CytomX Therapeutics' financial statements. These drivers represent accounts that assess CytomX Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of CytomX Therapeutics' important valuation drivers and their relationship over time.

	2020	2021	2022	2023	2024	2025 (projected)
Market Cap	302.3M	277.8M	105.2M	114.4M	87.0M	82.6M
Enterprise Value	135.3M	90.3M	(70.4M)	111.2M	58.3M	55.4M

CytomX Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, CytomX Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to CytomX Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

CytomX Therapeutics Institutional Holders

Institutional Holdings refers to the ownership stake in CytomX Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of CytomX Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing CytomX Therapeutics' value.

		Shares
Ra Capital Management, Llc	2025-03-31	1000 K
Geode Capital Management, Llc	2025-03-31	858 K
Gsa Capital Partners Llp	2025-03-31	762.9 K
Ubs Group Ag	2025-03-31	746.8 K
Assenagon Asset Management Sa	2025-06-30	720 K
Jacobs Levy Equity Management, Inc.	2025-03-31	686.2 K
Schonfeld Strategic Advisors Llc	2025-03-31	589.3 K
Sei Investments Co	2025-03-31	487.9 K
Bank Of America Corp	2025-03-31	463.9 K
Tang Capital Management Llc	2025-03-31	6.7 M
Bvf Inc	2025-03-31	5.2 M

CytomX Fundamentals

	Return On Equity	-54.75
	Return On Asset	0.16
	Profit Margin	0.28 %
	Operating Margin	0.44 %
	Current Valuation	296.92 M
	Shares Outstanding	157.54 M
	Shares Owned By Insiders	0.82 %
	Shares Owned By Institutions	49.81 %
	Number Of Shares Shorted	23.87 M
	Price To Earning	(11.41) X
	Price To Book	14.72 X
	Price To Sales	2.52 X
	Revenue	138.1 M
	Gross Profit	147.56 M
	EBITDA	26.76 M
	Net Income	31.87 M
	Cash And Equivalents	194.29 M
	Cash Per Share	2.94 X
	Total Debt	9.38 M
	Debt To Equity	0.67 %
	Current Ratio	2.05 X
	Book Value Per Share	0.31 X
	Cash Flow From Operations	(86.23 M)
	Short Ratio	10.34 X
	Earnings Per Share	0.48 X
	Price To Earnings To Growth	(1.80) X
	Target Price	5.75
	Number Of Employees	119
	Beta	2.13
	Market Capitalization	371.81 M
	Total Asset	120.53 M
	Retained Earnings	(691.58 M)
	Working Capital	21.53 M
	Current Asset	189.75 M
	Current Liabilities	15.74 M
	Net Asset	120.53 M

About CytomX Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze CytomX Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CytomX Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CytomX Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

USOI	Credit Suisse X Links
ULTY	Tidal Trust II
CONY	YieldMax N Option

Additional Tools for CytomX Stock Analysis

When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC